Hepatitis C, Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced Hepatocellular Carcinoma, Current Information On Hepatitis C & treatments for the medical professional and patient. | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Hepatitis C, Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced Hepatocellular Carcinoma, Current Information On Hepatitis C & treatments for the medical professional and patient.

Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced
Hepatocellular Carcinoma:
Results of a Randomized, Controlled Trial in a Single Institution

table 1. Baseline Characteristics of the Patients


TAE Group (n = 40) Control Group (n = 40)

Age (yr) 61 ± 9  64 ± 8 
Sex distribution (male/female) 30/10 30/10
Etiology of hepatic cirrhosis
  Hepatitis C virus 29 31
  Cryptogenic 5 4
  Alcohol 2 1
  Hepatitis B virus 2 1
  Others 2 3
Presence of ascites (%) 10 (25%) 7 (18%)
Constitutional syndrome (%) 9 (23%) 7 (18%)
Serum bilirubin (mg/dL) 1.2 ± 0.6 1.5 ± 0.7
Prothrombin activity (%) 81 ± 16 79 ± 14
Serum albumin (g/L) 35 ± 4  35 ± 5 
Alanine transaminase (UI/L)  89 ± 57  101 ± 75 
 -Glutamyltranspeptidase (UI/L) 112 ± 114 119 ± 88 
Alkaline phosphatase (UI/L) 303 ± 6   343 ± 201
Blood urea nitrogen (mg/dL) 18 ± 5  18 ± 5 
 -Fetoprotein
  100 ng/mL 26 27
  >100 ng/mL 14 13
Tumor stage
  Solitary 8 11
  Multinodular/massive 32 29
Tumor location
  Unilobar 24 25
  Bilobar 16 15
Child-Pugh score 5.8 ± 0.7 6.0 ± 1.1
Okuda’s stage (I/II) 27/13 27/13
PST (0/1/2) 27/11/2 27/11/2

NOTE. There were no significant differences between
groups with respect to any of these variables.

[Return To Article]